本文選題：卵巢癌 + GOLPH3表達(dá)�。� 參考：《大連醫(yī)科大學(xué)》2014年碩士論文

【摘要】：背和目的:高爾基體磷蛋白3(Golgi phosphoprotein3, GOLPH3)是于2009年6月才發(fā)現(xiàn)的癌基因，研究表明這種基因能促進(jìn)腫瘤細(xì)胞的生長(zhǎng)、分化和增殖，機(jī)制可能是調(diào)節(jié)哺乳動(dòng)物雷帕霉素靶蛋白（mammalian target of rapamycin,mTOR)信號(hào)通路，腫瘤細(xì)胞對(duì)雷帕霉素的敏感性也受此基因調(diào)節(jié)�，F(xiàn)有的研究提示Golph3在神經(jīng)膠質(zhì)瘤，前列腺癌,乳腺癌等均有明顯的表達(dá)，目前國(guó)內(nèi)外關(guān)于GOLPH3在腫瘤中表達(dá)的研究還比較少。本研究通過(guò)檢測(cè)GOLPH3在上皮性卵巢癌及正常卵巢組織中的表達(dá)，，探討GOLPH3,與上皮性卵巢癌臨床病理指標(biāo)的關(guān)系以及其是否能成為卵巢癌分子靶向治療又一新靶點(diǎn)。 方法：回顧分析31例上皮性卵巢癌患者及31例子宮良性腫瘤行卵巢切除患者的臨床及病理資料。采用免疫組化的方法(SP法)檢測(cè)31例上皮性卵巢癌組織、31例正常卵巢組織中GOLPH3的表達(dá);采用卡方檢驗(yàn)及秩和檢驗(yàn)等方法分GOLPH3表達(dá)與上皮性卵巢癌臨床病理因素的關(guān)系。 結(jié)果：1,GOLPH3免疫染色定位于細(xì)胞質(zhì)中主要有兩個(gè)模式，一是凝聚成較大的顆粒分布在細(xì)胞核周圍，二是以細(xì)顆粒的形式分散在細(xì)胞質(zhì)中,GOLPH3在上皮性卵巢癌中的表達(dá)與在正常卵巢組織中表達(dá)相比有顯著增高，差異具有統(tǒng)計(jì)學(xué)意義(x2=47.032P0.05)。 2，GOLPH3在上皮性卵巢癌不同分期、不同分級(jí)分組間的陽(yáng)性表達(dá)強(qiáng)度差異也同樣具有統(tǒng)計(jì)學(xué)意義(P0.05)，且其陽(yáng)性表達(dá)隨分期、分級(jí)的增高而增強(qiáng)(P0.05),但在年齡、病理組織類型分組中的表達(dá)差異沒(méi)有統(tǒng)計(jì)學(xué)意義(p0.05)。 結(jié)論:1, GOLPH3在上皮性卵巢癌中的陽(yáng)性表達(dá)率明顯高于正常卵巢組織，提示上皮性卵巢癌的發(fā)生與GOLPH3的異常表達(dá)之間存在密切相關(guān)性。 2,隨著腫瘤的分期、分級(jí)的增高，GOLPH3在上皮性卵巢癌中的陽(yáng)性表達(dá)也增強(qiáng)，從而提示GOLPH3表達(dá)強(qiáng)度與上皮性卵巢癌惡性程度及腫瘤進(jìn)展程度成正向相關(guān)，GOLPH3也許能成為輔助判斷上皮性卵巢癌預(yù)后好壞的標(biāo)志物,需要進(jìn)一步研究。 3, GOLPH3在上皮性卵巢癌組織中高表達(dá)現(xiàn)象，提示GOLPH3很可能成為卵巢癌靶向治療的一個(gè)有利靶點(diǎn)
[Abstract]:Back and objective: Golgi phosphoprotein 3 (GOLPH3) is a oncogene discovered in June 2009, which has been shown to promote the growth, differentiation and proliferation of tumor cells. The mechanism may be the regulation of mammalian rapamycin target protein mammalian target of rapamycin mTOR. the sensitivity of tumor cells to rapamycin is also regulated by this gene. The existing studies suggest that Golph3 is expressed in gliomas, prostate cancer, breast cancer and so on. At present, there are few studies on the expression of GOLPH3 in tumors at home and abroad. In this study, we examined the expression of GOLPH3 in epithelial ovarian carcinoma and normal ovarian tissues, and explored the relationship between GOLPH3 and clinicopathological parameters of epithelial ovarian cancer and whether it could be a new target for molecular targeted therapy of ovarian cancer. Methods: the clinical and pathological data of 31 patients with epithelial ovarian cancer and 31 patients with benign uterine tumor were retrospectively analyzed. Immunohistochemical method was used to detect the expression of GOLPH3 in 31 normal ovarian tissues from 31 cases of epithelial ovarian carcinoma and the relationship between GOLPH3 expression and clinicopathological factors of epithelial ovarian carcinoma was analyzed by chi-square test and rank sum test. Results there were two main patterns in the cytoplasm of the cytoplasm, one was the aggregation of larger particles around the nucleus, and the other was the distribution of large particles around the nucleus. The expression of GOLPH3 in epithelial ovarian carcinoma was significantly higher than that in normal ovarian tissue, and the difference was statistically significant. 2the positive expression intensity of GOLPH3 in different stages of epithelial ovarian cancer was also significantly different among different grading groups, and the positive expression of GOLPH3 increased with the stage and grade, but at the age, the positive expression of GOLPH3 was increased with the stage and grade of ovarian carcinoma, but at the age, the positive expression of GOLPH3 was increased with the stage and grade of epithelial ovarian cancer. There was no significant difference in the expression of P0. 05 in the histopathologic groups. Conclusion the positive expression rate of GOLPH3 in epithelial ovarian carcinoma is significantly higher than that in normal ovarian tissue, suggesting that there is a close correlation between the occurrence of epithelial ovarian cancer and abnormal expression of GOLPH3. 2. With the stage of the tumor, the positive expression of GOLPH3 in epithelial ovarian cancer was also increased with the increase of grade. The results suggest that the positive correlation between the expression of GOLPH3 and the malignant degree and progression of epithelial ovarian cancer may be a marker of the prognosis of epithelial ovarian cancer, which needs further study. 3. The overexpression of GOLPH3 in epithelial ovarian cancer tissues suggests that GOLPH3 may be a favorable target for the targeted therapy of ovarian cancer.
【學(xué)位授予單位】：大連醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.31

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 燕鑫,陳春玲,張巖,廖秦平;61例復(fù)發(fā)性上皮性卵巢癌相關(guān)臨床因素分析[J];中國(guó)婦產(chǎn)科臨床雜志;2004年03期

2 呂藝;;上皮性卵巢癌ki-67基因表達(dá)及意義[J];黑龍江醫(yī)學(xué);2008年01期

3 米愛(ài);;研究證實(shí)喝咖啡可抗癌[J];科學(xué)大觀園;2008年08期

4 俞遠(yuǎn)京;蘇志杰;周智君;馬亞?wèn)|;;東方田鼠卵巢癌模型病理學(xué)觀察[J];中國(guó)獸醫(yī)學(xué)報(bào);2008年09期

5 楊麗娜;;卵巢癌靜脈化療的血管護(hù)理[J];山東醫(yī)藥;2008年31期

6 王弋;胡芝;柯曉慧;蔣聯(lián)萍;;飛行時(shí)間質(zhì)譜技術(shù)篩查上皮性卵巢癌患者血清特異性蛋白的研究[J];中國(guó)中西醫(yī)結(jié)合外科雜志;2009年06期

7 東梅;徐楊;張頤;;NF-κB在上皮性卵巢癌中的表達(dá)及其臨床意義[J];遼寧醫(yī)學(xué)雜志;2010年01期

8 黃翠萍;林偉;王翔宇;王蓁;;上皮性卵巢癌組織中uPA及uPAR的表達(dá)(英文)[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2010年01期

9 向江東;李雙弟;張佳榮;王炎秋;楊懿霞;劉雪蓮;席曉薇;萬(wàn)小平;;特異AT序列結(jié)合蛋白1在卵巢癌的表達(dá)及臨床病理學(xué)意義[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2010年07期

10 黃春梅;;晚期上皮性卵巢癌的綜合治療效果分析[J];實(shí)用醫(yī)藥雜志;2007年04期

相關(guān)會(huì)議論文 前10條

1 蔡U

本文編號(hào)：1849622